6/27/2025

Janusmed sex and gender

Janusmed sex and gender – oxaliplatin

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C! C!
C! C!

Oxaliplatin

Oxaliplatin

Class : C!

Show all info

Print

Contact us

  1. Bastian G, Barrail A, Urien S. Population pharmacokinetics of oxaliplatin in patients with metastatic cancer. Anticancer Drugs. 2003;14(10):817-24.

  2. Kim J, Ji E, Jung K, Jung IH, Park J, Lee JC et al. Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX. J Pers Med. 2021;11(2):.

  3. Lambert A, Jarlier M, Gourgou Bourgade S, Conroy T. Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial. PLoS One. 2017;12(9):e0183288.

  4. Hohla F, Hopfinger G, Romeder F, Rinnerthaler G, Bezan A, Stättner S et al. Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review. Int J Oncol. 2014;44(1):319-26.

  5. Pan X, Xiao X, Ding Y, Shu Y, Zhang W, Huang L. Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system. Front Pharmacol. 2024;15:1431579.

  6. Díaz R, Aparicio J, Molina J, Palomar L, Giménez A, Ponce J et al. Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer: a single center experience. Med Oncol. 2006;23(3):347-57.

  7. Suzuki A, Kobayashi R, Fujii H, Iihara H, Takahashi T, Yoshida K et al. Control of Nausea and Vomiting in Patients with Colorectal Cancer Receiving Chemotherapy with Moderate Emetic Risk. Anticancer Res. 2016;36(12):6527-6533.

  8. Kim BH, Bradley T, Tai J, Budman DR. Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. Oncology. 2009;76(4):231-8.

  9. Oxaliplatin Accord (oxaliplatin). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2024-11-04, cited 2025-05-19]

  1. Bastian G, Barrail A, Urien S. Population pharmacokinetics of oxaliplatin in patients with metastatic cancer. Anticancer Drugs. 2003;14(10):817-24.
  2. Kim J, Ji E, Jung K, Jung IH, Park J, Lee JC et al. Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX. J Pers Med. 2021;11(2):.
  3. Lambert A, Jarlier M, Gourgou Bourgade S, Conroy T. Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial. PLoS One. 2017;12(9):e0183288.
  4. Hohla F, Hopfinger G, Romeder F, Rinnerthaler G, Bezan A, Stättner S et al. Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review. Int J Oncol. 2014;44(1):319-26.
  5. Pan X, Xiao X, Ding Y, Shu Y, Zhang W, Huang L. Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system. Front Pharmacol. 2024;15:1431579.
  6. Díaz R, Aparicio J, Molina J, Palomar L, Giménez A, Ponce J et al. Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer: a single center experience. Med Oncol. 2006;23(3):347-57.
  7. Suzuki A, Kobayashi R, Fujii H, Iihara H, Takahashi T, Yoshida K et al. Control of Nausea and Vomiting in Patients with Colorectal Cancer Receiving Chemotherapy with Moderate Emetic Risk. Anticancer Res. 2016;36(12):6527-6533.
  8. Kim BH, Bradley T, Tai J, Budman DR. Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. Oncology. 2009;76(4):231-8.
  9. Oxaliplatin Accord (oxaliplatin). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2024-11-04, cited 2025-05-19]